Advertisement

Issue 26, Volume 127

Cover Figure: Impaired dendritic cell function in patients with Hermansky-Pudlak syndrome type 2. See the article by Prandini et al.

WASHINGTON, June 30,  2016 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Human neutrophil kinetics: modeling of stable isotope labeling data supports short blood neutrophil half-lives
Recent studies have challenged the traditional dogma that the half-life of neutrophils in the peripheral blood is less than 24 hours. Lahoz-Beneytez and colleagues reexamine this question using stable deuterium labeling and confirm that neutrophil half-life is 13-19 hours, as predicted several decades ago.

Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm
Current evidence suggests that although Jak2V617F is sufficient to induce polycythemia vera, further mutations are required to progress to myelofibrosis. A subset of patients with JAK2+ myelofibrosis have inactivating EZH2 mutations. Yang and colleagues demonstrate that loss of Ezh2 in Jak2V617F mice inhibits erythropoiesis, increases thrombocytosis, and rapidly induces myelofibrosis.

Recurrent abnormalities can be used for risk group stratification in pediatric AMKL: a retrospective intergroup study
Non-Down syndrome acute megakaryoblastic leukemia (AMKL) is a rare poor-prognosis subtype of pediatric acute myeloid leukemia, but until now its rarity has precluded adequate risk stratification. de Rooij and colleagues report the outcome of deep sequencing of 153 cases of AMKL, and they identify molecular abnormalities that allow better assessment of risk and could lead to more targeted therapy of this rare malignancy.

Single- vs double-unit cord blood transplantation for children and young adults with acute leukemia or myelodysplastic syndrome
Michel and colleagues report that single umbilical cord (UBC) transplant, if available in adequate cell numbers, is superior to double UBC transplant in children and young adults with acute myeloid leukemia or myelodysplastic syndrome. Single-unit transplant is associated with equivalent engraftment and remission-free survival, lower rates of chronic graft-versus-host disease, and less transplant-related mortality.

Introduction to a review series on advances in cell-based immune therapeutics in hematology
We present a review series on cell-based immunotherapy. This six-part series written by leading experts in the field presents three articles discussing the state of the art of chimeric antigen receptor T-cell therapies and their toxicities and three additional articles that highlight other new immunotherapeutic approaches, including cellular therapies to treat post–hematopoietic stem cell transplantation viral infections, natural killer cell therapies for acute leukemia, and the use of gene-modified T cells to block immune evasion in hematologic malignancies.

The articles in this review series, "Advances in Cell-based Immune Therapeutics, " include the following:

 

This week's complete table of contents

Why Submit to Blood?

Join the "This Week in Blood" mailing list by filling out the form below and clicking Subscribe!
*Email Address:
*First Name:
*Last Name:

 

Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.